Free Trial
OTCMKTS:NBIO

Nascent Biotech (NBIO) Stock Price, News & Analysis

Nascent Biotech logo

About Nascent Biotech Stock (OTCMKTS:NBIO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
58,265 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. The company has collaboration with Hypospray Pharma to develop an alternative delivery mechanism for patients who can benefit from Pritumumab. Nascent Biotech, Inc. is based in North Palm Beach, Florida.

Receive NBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nascent Biotech and its competitors with MarketBeat's FREE daily newsletter.

NBIO Stock News Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
Nascent Biotech Inc NBIO
See More Headlines

NBIO Stock Analysis - Frequently Asked Questions

Shares of NBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nascent Biotech investors own include Fulcrum Therapeutics (FULC), Evelo Biosciences (EVLO), VIVUS (VVUS), Applied Therapeutics (APLT), Ocugen (OCGN), Processa Pharmaceuticals (PCSA) and Rigel Pharmaceuticals (RIGL).

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:NBIO
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (OTCMKTS:NBIO) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners